Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

1.

Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.

Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, Schwartz M, Krasnansky J, Pencer E, Silva-Vazquez L, Kirby KC, Royer-Malvestuto C, Roll JM, Cohen A, Copersino ML, Kolodner K, Li R.

Arch Gen Psychiatry. 2006 Feb;63(2):201-8.

PMID:
16461864
[PubMed - indexed for MEDLINE]
2.

Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.

Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, Liebert M, Rader L, Burns R, DiMaria J, Copersino M, Stabile PQ, Kolodner K, Li R.

Arch Gen Psychiatry. 2005 Oct;62(10):1148-56.

PMID:
16203960
[PubMed - indexed for MEDLINE]
3.

Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.

Knudsen HK, Ducharme LJ, Roman PM, Link T.

J Subst Abuse Treat. 2005 Sep;29(2):95-106.

PMID:
16135338
[PubMed - indexed for MEDLINE]
4.

Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs.

Saxon AJ, McCarty D.

Pharmacol Ther. 2005 Oct;108(1):119-28. Review.

PMID:
16055196
[PubMed - indexed for MEDLINE]
5.

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D; Buprenorphine Study Protocol Group.

Addiction. 2005 Aug;100(8):1090-100. Erratum in: Addiction. 2006 Sep;101(9):1374.

PMID:
16042639
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Adoption of naltrexone to treat alcohol dependence.

Fuller BE, Rieckmann T, McCarty D, Smith KW, Levine H.

J Subst Abuse Treat. 2005 Apr;28(3):273-80.

PMID:
15857728
[PubMed - indexed for MEDLINE]
7.

The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer.

Laliberte L, Fennell ML, Papandonatos G.

Med Care. 2005 May;43(5):471-9.

PMID:
15838412
[PubMed - indexed for MEDLINE]
8.

Something of value: the introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service.

Kellogg SH, Burns M, Coleman P, Stitzer M, Wale JB, Kreek MJ.

J Subst Abuse Treat. 2005 Jan;28(1):57-65.

PMID:
15723733
[PubMed - indexed for MEDLINE]
9.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

PMID:
15204675
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom?

Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ.

Addiction. 2004 Mar;99(3):349-60.

PMID:
14982548
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Modeling the use of innovations in private treatment organizations: the role of absorptive capacity.

Knudsen HK, Roman PM.

J Subst Abuse Treat. 2004 Jan;26(1):353-61.

PMID:
14698799
[PubMed - indexed for MEDLINE]
12.

Understanding US addiction physicians' low rate of naltrexone prescription.

Mark TL, Kranzler HR, Song X.

Drug Alcohol Depend. 2003 Sep 10;71(3):219-28.

PMID:
12957340
[PubMed - indexed for MEDLINE]
13.

Buprenorphine: how to use it right.

Johnson RE, Strain EC, Amass L.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77. Review.

PMID:
12738351
[PubMed - indexed for MEDLINE]
14.

Clinical efficacy of buprenorphine: comparisons to methadone and placebo.

Ling W, Wesson DR.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S49-57. Review.

PMID:
12738350
[PubMed - indexed for MEDLINE]
15.

Research to practice: adoption of naltrexone in alcoholism treatment.

Thomas CP, Wallack SS, Lee S, McCarty D, Swift R.

J Subst Abuse Treat. 2003 Jan;24(1):1-11.

PMID:
12646325
[PubMed - indexed for MEDLINE]
16.

Recent advances in the dissemination of contingency management techniques: clinical and research perspectives.

Petry NM, Simcic F Jr.

J Subst Abuse Treat. 2002 Sep;23(2):81-6. Review.

PMID:
12220605
[PubMed - indexed for MEDLINE]
17.

Putting drug abuse research to use in real-life settings.

Hanson GR, Leshner AI, Tai B.

J Subst Abuse Treat. 2002 Sep;23(2):69-70. No abstract available.

PMID:
12220602
[PubMed - indexed for MEDLINE]
18.

Adoption and implementation of new technologies in substance abuse treatment.

Roman PM, Johnson JA.

J Subst Abuse Treat. 2002 Jun;22(4):211-8.

PMID:
12072165
[PubMed - indexed for MEDLINE]
19.

A conceptual framework for transferring research to practice.

Simpson DD.

J Subst Abuse Treat. 2002 Jun;22(4):171-82.

PMID:
12072162
[PubMed - indexed for MEDLINE]
20.

Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients.

Petry NM, Martin B.

J Consult Clin Psychol. 2002 Apr;70(2):398-405.

PMID:
11952198
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk